EGFR and glioblastoma: There have been several trials of EGFR inhibitors in GBM, mainly using small molecular ATP-competitive tyrosine kinase inhibitors Several phase II trials of EGFR inhibitors such as erlotinib or gefitinib have demonstrated limited effectiveness of these agents for gliomas[14].